Prediabetes

The U.S. Centers for Disease Control and Prevention (CDC) Recognize Herbalife’s Lifestyle Intervention Program as a Certified Diabetes Prevention Program

Retrieved on: 
Tuesday, November 14, 2023
Other Consumer, Diabetes, Marketing, Fitness & Nutrition, Communications, Alternative Medicine, Health, Consumer, General Health, Nutrition, Incidence, Ageing, Herbalife, National Diabetes Education Program, Risk, CDC, Type 2 diabetes, The Lancet, Prediabetes, Certification, Weight loss, Pharmaceutical industry

In support of November being Diabetes Prevention Month, Herbalife, a premier health and wellness company, announced today that its Lifestyle Intervention Program is recognized by the Centers for Disease Control and Prevention (CDC), the national public health agency of the United States as complying with their standards for a CDC Certified Diabetes Prevention Program .

Key Points: 
  • In support of November being Diabetes Prevention Month, Herbalife, a premier health and wellness company, announced today that its Lifestyle Intervention Program is recognized by the Centers for Disease Control and Prevention (CDC), the national public health agency of the United States as complying with their standards for a CDC Certified Diabetes Prevention Program .
  • November is National Diabetes Awareness Month and according to the CDC and Prevention, about 38 million Americans live with diabetes and 97 million with prediabetes, a health condition that can lead to type 2 diabetes.
  • A CDC-recognized lifestyle change program is an evidence-based solution that can reduce a person’s risk of developing type 2 diabetes by 58% and 71% in individuals aged 65 and older.
  • “We are excited that we will be offering a CDC recognized lifestyle change program, a curriculum-based approach that focuses on behavior change to help improve weight loss, and is backed by scientific evidence,” said Dr. Kent Bradley, Herbalife’s Chief Health and Nutrition Officer.

Cleerly, Partners Announce TRANSFORM Trial to Evaluate Personalized Heart Disease Care Strategies at American Heart Association 2023

Retrieved on: 
Saturday, November 11, 2023
Health, Technology, Health Technology, Clinical Trials, Artificial Intelligence, Pharmaceutical, Cardiology, Esperion Therapeutics, Participation, Ezetimibe, Atherosclerosis, Therapy, FAHA, Plaque, FACC, AHA, Cholesterol, Risk, CCTA, Cardiovascular disease, CAD, Tablet, Patient, Myocardial infarction, Bempedoic acid, Molina Healthcare, LDL, Type 2 diabetes, American Heart Association, University, Diagnosis, Pulmonary Vascular Research Institute, MPH, FESC, Splenic infarction, ASCVD, AI, Metabolic syndrome, Prediabetes, American Heart, Moyamoya disease, Pharmaceutical industry, Dietary supplement, Management, Medical imaging, Medicine, MD

Cleerly , the company working to create a new standard of care for the diagnosis of heart disease, today announced the TRANSFORM trial at the American Heart Association’s (AHA) 2023 Scientific Sessions.

Key Points: 
  • Cleerly , the company working to create a new standard of care for the diagnosis of heart disease, today announced the TRANSFORM trial at the American Heart Association’s (AHA) 2023 Scientific Sessions.
  • TRANSFORM is a randomized trial – sponsored by Cleerly – that aims to enroll 7,500 patients who have pre-diabetes, type 2 diabetes, or metabolic syndrome and have no symptoms of heart disease.
  • TRANSFORM aims to prove that a personalized care strategy based on a Cleerly analysis is better than usual care based on traditional cardiovascular risk factors for the primary prevention of cardiovascular events.
  • “This trial provides us the opportunity to revolutionize cardiovascular event prevention and ultimately save lives from heart disease.

Confronting "Tripledemic," Americans Are Concerned About Cough Syrup Effectiveness and Formulas with Hidden Sugars

Retrieved on: 
Monday, December 18, 2023
Holiday, Pharmacist, American Diabetes Association, COVID-19, Prestige Consumer Healthcare, Research, Diabetes, Prediabetes, RSV, Face, Travel, Blood pressure, Pharmaceutical industry, Dietary supplement, Amazon

TARRYTOWN, N.Y., Dec. 18, 2023 /PRNewswire/ -- Diabetic Tussin®, the trusted cough syrup brand for people with diabetes and prediabetes, unveils new data revealing consumers' realities and worries as they navigate the rising threat of a "tripledemic" — flu, RSV (respiratory syncytial virus) and COVID-19 — coinciding with the arrival of cold season.

Key Points: 
  • Consumers are also navigating a cold and flu season that is extending, with 37% getting sick earlier and 43% staying sick for longer periods than ever before.
  • "As the trusted brand for sugar-free cold and cough syrup, Diabetic Tussin can do just that.
  • Over 71% of people get sick once or twice during cold and flu season, with 14% getting sick three times.
  • To learn more about Diabetic Tussin, visit www.diabetictussin.com or check out the brand in Dollar General stores nationwide and on Amazon.

TWIN HEALTH SECURES $50M TO EXPAND ITS GROUNDBREAKING WHOLE BODY DIGITAL TWIN™ TECHNOLOGY AND SERVICE TO REVERSE CHRONIC METABOLIC DISEASE

Retrieved on: 
Wednesday, December 13, 2023
RCT, Sleep, NAFLD, Whole-body vibration, Randomized controlled trial, Type, Temasek, Liver disease, DSM-IV codes, Growth, Metabolic syndrome, Metabolism, Type 2 diabetes, Artificial intelligence, Obesity, Non-alcoholic fatty liver disease, Machine learning, Digital twin, Dyslipidemia, Health, ICONIQ, Digital, CDC, Prediabetes, Weight loss, Medical imaging, Pharmaceutical industry, Starbucks

MOUNTAIN VIEW, Calif., Dec. 13, 2023 /PRNewswire/ -- Twin Health, creators of the Whole Body Digital Twin™ service for reversing, improving, and preventing chronic metabolic diseases, announced securing $50 million in funding to continue expanding its groundbreaking technology and clinical service solutions for more members across the United States.

Key Points: 
  • Through an easy-to-use app, the Whole Body Digital Twin provides members and their Twin Health licensed clinical care team individualized, precise, timely guidance across nutrition, sleep, activity and stress.
  • Twin Health's chronic metabolic disease solution is available today through Twin Health's employer and health plan partners.
  • Twin Health has expanded its reach with strategic partners in the employer and health plan domains, covering over 4 million lives.
  • Notable achievements include completing the world's first randomized controlled trial (RCT) for reversing chronic metabolic disease using digital twin technology.

Introducing A1C Drinks: A Healthy and Delicious Beverage to Control Blood Sugar

Retrieved on: 
Monday, December 11, 2023
Aloe, Diet, Research, Drink, Vanilla, Energy, American Heart Association, Overweight, Aloe vera, Sugar, Type 2 diabetes, Obesity, NFL, Cola, Health, Heart Association, Child, Water, Public health, Diabetes, Sport, Prediabetes, Life, Dietary supplement, Soft drink, Bottled water, Online shopping, Medicine

OVERLAND PARK, Kan., Dec. 11, 2023 /PRNewswire/ -- Introducing A1C Drinks, a new brand of healthy, delicious beverages designed to help people manage their blood sugar, weight, diabetes and pre-diabetes. The drink is also helping fight childhood obesity, and provides an alternative to sugary sodas and sports drinks, making it perfect for anyone who cares about their health.

Key Points: 
  • For those managing their blood sugar levels, these drinks offer flavor and refreshment without adverse impacts on health.
  • Science Backed: A1C Drinks are rooted in scientific research, to offer health benefits supported by the latest insights in nutritional studies.
  • Exceptional Ingredients: A1C Drinks are crafted using the highest quality ingredients, with pure cinnamon at the forefront - a spice renowned for supporting healthy blood sugar levels.
  • For more information on A1C Drinks, visit: www.A1CDrinks.com
    To find a store that carries A1C Drinks, visit: www.a1cdrinks.com/store-locator
    If you are a retailer interested in carrying A1C Drinks, visit: www.a1cdrinks.com/retailer-application
    To buy A1C Drinks online, visit: www.a1cdrinks.com/shop

The American Diabetes Association Releases the Standards of Care in Diabetes--2024

Retrieved on: 
Monday, December 11, 2023
Epidemiology, AID, Standard of care, Infection, PPC, Gestational diabetes, Diagnosis, CVD, Disability, Doctor of Philosophy, Mental health, Abridgement, Prediabetes, Diabetes, Knowledge, Webcast, NAFLD, RSV, Endocrinology, Fatty liver disease, Kidney disease, Cardiovascular disease, Fracture, Moyamoya disease, Society, Physician, Public, Hypoglycemia, Waist, Practitioner, PAD, Risk, Pharmacist, GIP, C-peptide, Artificial intelligence, Immunization, Conditional sentence, Section 4, Body mass index, Himawari (satellites), Classification, The Obesity Society, American Diabetes Association, Vaccine, Obesity, American College, Heart failure, COVID-19, Dietary supplement, Nursing, Landscape maintenance, Pharmaceutical industry, Medical device, Dentistry, MD

ARLINGTON, Va., Dec. 11, 2023  /PRNewswire/ -- Today, the American Diabetes Association® (ADA) released the Standards of Care in Diabetes—2024 (Standards of Care), a set of comprehensive and evidence-based guidelines for managing type 1, type 2, gestational diabetes, and prediabetes based on the latest scientific research and clinical trials. It includes strategies for diagnosing and treating diabetes in both youth and adults, methods to prevent or delay type 2 diabetes and its associated comorbidities like cardiovascular disease (CVD) and obesity, and therapeutic approaches aimed at minimizing complications and enhancing health outcomes.

Key Points: 
  • "The latest ADA guidelines present pivotal updates for health care professionals, ensuring comprehensive, evidence-based care for diabetes management.
  • "The ADA's Standards of Care ensures health care professionals, especially our primary care workforce, provide the best possible care to those living with diabetes."
  • The Standards of Care are critical to ensuring the improved treatment of diabetes, a chronic disease that requires continuous care through a well-informed and coordinated health care team.
  • Today, the Standards of Care in Diabetes—2024 is available online and is published as a supplement to the January 2024 issue of Diabetes Care® .

National Employer Selects Dario Cardiometabolic and GLP-1 Solutions to Improve Employee Health

Retrieved on: 
Tuesday, December 5, 2023
Employment, Hypertension, Diabetes, Prediabetes, Pharmaceutical industry

NEW YORK, Dec. 5, 2023 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced today a new contract to provide cardiometabolic and GLP-1 solutions to a national employer (the "Employer") beginning in January 2024.

Key Points: 
  • The Employer, a national logistics company, selected Dario to deliver integrated support for employees living with diabetes, pre-diabetes, weight management and hypertension, while also providing a tailored experience for employees taking a GLP-1 medication.
  • Dario combines intelligent technologies and expert human support with billions of data insights gathered from a decade of consumer engagement to deliver highly personalized experiences that keep people engaged over time for optimal results.
  • "GLP-1 medications are creating tremendous upheaval for employers and payers, and our new contract with the Employer is a great example of how Dario is helping employers address the growing and costly problem.
  • Dario's solutions have been proven, in prior studies, to deliver long-term behavior change with and without a GLP-1 medication to help employers like the Employer realize the full potential in health outcomes," said Rick Anderson, President of Dario.

Diabetic Tussin Reintroduces Sugar-Free Cold and Cough Solution for People with Diabetes

Retrieved on: 
Wednesday, November 29, 2023
Cough, RSV, National Diabetes Education Program, Congestion, Risk, Better Choice Parking, Prestige Consumer Healthcare, American Diabetes Association, Fructose, Sorbitol, Mucus, COVID-19, Dollar, Blood, Diabetes, Prediabetes, Sodium, Pharmaceutical industry, Amazon

TARRYTOWN, N.Y., Nov. 29, 2023 /PRNewswire/ -- Today, Diabetic Tussin®, the trusted cough syrup brand for people with diabetes and prediabetes, announces its sugar-free cold and cough solution is back on shelves. This restock brings with it the Better Choices for Life mark from the American Diabetes Association® (ADA). This over-the-counter cold and cough solution returns just as the threat of a 'tripledemic' — when cases of COVID-19, flu, and RSV surge at the same time—looms over American households.

Key Points: 
  • TARRYTOWN, N.Y., Nov. 29, 2023 /PRNewswire/ -- Today, Diabetic Tussin®, the trusted cough syrup brand for people with diabetes and prediabetes, announces its sugar-free cold and cough solution is back on shelves.
  • This over-the-counter cold and cough solution returns just as the threat of a 'tripledemic' — when cases of COVID-19, flu, and RSV surge at the same time—looms over American households.
  • "Diabetic Tussin is an essential over-the-counter cold and cough solution for millions of Americans concerned about ingredients in other products that can raise blood sugar levels.
  • Made with the strongest sugar-free formula on the market, Diabetic Tussin Max allows consumers to effectively manage their cough and cold symptoms with the right ingredients.

Dario Contracts with New Employer for Cardiometabolic Solution

Retrieved on: 
Monday, November 27, 2023
Employment, Hypertension, Diabetes, Prediabetes

NEW YORK, Nov. 27, 2023 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced today a new contract to provide its cardiometabolic solution to an employer (the "Employer") beginning in January 2024.

Key Points: 
  • NEW YORK, Nov. 27, 2023 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced today a new contract to provide its cardiometabolic solution to an employer (the "Employer") beginning in January 2024.
  • The Employer, a national financial and business services company, selected Dario to improve the cardiometabolic health of its population with an integrated solution for diabetes, pre-diabetes, weight management and hypertension along with tailored support for employees taking a GLP-1, or anti-obesity, medications.
  • "Dario is seeing increased interest in our proven ability to help people achieve better cardiometabolic health through sustained behavior change, a requirement for people using medications such as GLP-1s.
  • We are excited to support our new client's business goals with effective and easy-to-use solutions which we believe employees will love," said Rick Anderson, President of Dario.

Capital Rx and Vida Health Partner to Launch Rx Activate, a High-Touch Chronic Condition Management Program

Retrieved on: 
Tuesday, November 14, 2023
Mental, COPD, Hypertension, Heart, Depression, Social isolation, Doctor of Pharmacy, Patient, Health, Anxiety, PBA, Hyperlipidemia, Diabetes, Prediabetes, Asthma, PBM, Food, Cryptocurrency, Pharmaceutical industry, Nursing

Rx Activate combines Capital Rx's JUDI® with Vida's solutions to address some of the most prevalent chronic conditions.

Key Points: 
  • Rx Activate combines Capital Rx's JUDI® with Vida's solutions to address some of the most prevalent chronic conditions.
  • With chronic conditions driving over $3.6 trillion in total healthcare expenditures in the U.S., it's hard to ignore the problem plan sponsors face.
  • Capital Rx and Vida are addressing some fundamental gaps in care with a formulary- and benefit-aligned program: Rx Activate includes high-touch medication management supported by exceptional member service to build trust with providers and patients and help bring down the total cost of care.
  • Together, JUDI and Vida's digital tools can offer chronic condition management and high-touch cardiometabolic care that delivers equitable health outcomes, addressing members regardless of socioeconomic status.